When doctors notice a cancer patient's blood work, they're learning to pay attention to an unexpected culprit: vitamin B12 levels that are unusually high. For decades, the nutritional wisdom seemed straightforward—B12, also known as cobalamin, is essential for life, helping the body produce red blood cells, maintain nervous system function, and perform the critical task of copying and repairing DNA. But recent research is revealing that the relationship between this vital nutrient and cancer is far more nuanced than "more is better."
The paradox lies at the heart of how cells work. B12 is genuinely critical to DNA replication, which means deficiency can lead to errors in copying genetic material that, over years, may increase cancer risk—particularly colon cancer. This danger is real and well-established. Yet the body's need for balance extends in both directions. A 2025 case-control study from Vietnam found what researchers described as a U-shaped relationship between B12 intake and cancer risk, with both lower and higher intakes associated with increased risk. The insight is neither that B12 is dangerous nor that more is protective, but that equilibrium matters.
The logic of supplementation seems sound: if B12 supports healthy cell growth, wouldn't extra doses offer extra protection? The answer, based on current evidence, is no. While B12 does support cell growth generally, it supports the growth of all cells—healthy and pre-cancerous alike. High-dose B vitamin supplements taken over long periods have not shown clear protective effects against cancer incidence or death, with one narrow exception: a reduced risk of melanoma. Some observational research has even suggested a slight increase in lung cancer risk linked to long-term, high-dose B6 and B12 supplementation, particularly among men and smokers, though such studies cannot prove causation.
The real surprise came when researchers noticed something unexpected: many cancer patients show unusually high B12 levels in their blood. This sparked a critical question—is elevated B12 driving cancer, or is cancer itself causing B12 to rise? Research from 2022 and 2024 provided an answer: high B12 in cancer patients is often an "epiphenomenon," meaning the vitamin appears alongside the disease but does not necessarily trigger it. Two mechanisms explain this. First, tumors can damage the liver, which stores large amounts of B12, causing it to release more into the bloodstream. Second, some tumors increase proteins that bind to B12, pushing blood test readings higher without necessarily meaning cells are receiving more of the nutrient.
What's emerging now is even more significant: elevated B12 may serve as a diagnostic marker. A large 2026 study found that colon cancer patients with very high B12 levels survived a median of around five years, compared with nearly eleven years for those with normal levels. Similar patterns have appeared in oral cancer and among patients receiving immunotherapy, where elevated B12 has been associated with poorer outcomes. This means that unexplained, persistent high B12—especially when not caused by supplements—warrants medical attention and may point to liver disease, blood disorders, or undetected cancer.
For most people following a varied diet with meat, fish, eggs, dairy, or fortified foods, this research raises no alarm bells. It's nearly impossible to consume excess B12 from food alone. The concern centers on prolonged high-dose supplementation without medical guidance, or persistent elevated B12 in blood tests when someone isn't taking supplements. The broader message remains reassuringly simple: balance matters, and context is everything.